Header Logo

Connection

PAVAN REDDY to Adult

Back to Details
This is a "connection" page, showing publications PAVAN REDDY has written about Adult.
PAVAN REDDY
Connection Strength
0.365
Adult
  1. A phase 2 trial of CD24Fc for prevention of graft-versus-host disease. Blood. 2024 01 04; 143(1):21-31.
    View in: PubMed
    Score: 0.049
  2. Feasibility of a dietary intervention to modify gut microbial metabolism in patients with hematopoietic stem cell transplantation. Nat Med. 2023 11; 29(11):2805-2813.
    View in: PubMed
    Score: 0.048
  3. a1-Antitrypsin infusion for treatment of steroid-resistant acute graft-versus-host disease. Blood. 2018 03 22; 131(12):1372-1379.
    View in: PubMed
    Score: 0.033
  4. Vorinostat plus tacrolimus/methotrexate to prevent GVHD after myeloablative conditioning, unrelated donor HCT. Blood. 2017 10 12; 130(15):1760-1767.
    View in: PubMed
    Score: 0.031
  5. Histone deacetylase inhibition regulates inflammation and enhances Tregs after allogeneic hematopoietic cell transplantation in humans. Blood. 2015 Jan 29; 125(5):815-9.
    View in: PubMed
    Score: 0.026
  6. Vorinostat plus tacrolimus and mycophenolate to prevent graft-versus-host disease after related-donor reduced-intensity conditioning allogeneic haemopoietic stem-cell transplantation: a phase 1/2 trial. Lancet Oncol. 2014 Jan; 15(1):87-95.
    View in: PubMed
    Score: 0.024
  7. Oral inflammation and microbiome dysbiosis exacerbate chronic graft-versus-host disease. Blood. 2025 Feb 20; 145(8):881-896.
    View in: PubMed
    Score: 0.013
  8. Bacteroides ovatus alleviates dysbiotic microbiota-induced graft-versus-host disease. Cell Host Microbe. 2024 Sep 11; 32(9):1621-1636.e6.
    View in: PubMed
    Score: 0.013
  9. Recruitment and Retention of Hematopoietic Cell Transplantation and Cellular Therapy Physicians: A Report from the ASTCT Talent Acquisition Task Force. Transplant Cell Ther. 2024 06; 30(6):559-564.
    View in: PubMed
    Score: 0.012
  10. A Phase 2 Study of Pembrolizumab during Lymphodepletion after Autologous Hematopoietic Cell Transplantation for Multiple Myeloma. Biol Blood Marrow Transplant. 2019 08; 25(8):1492-1497.
    View in: PubMed
    Score: 0.009
  11. Assessment of Individual versus Composite Endpoints of Acute Graft-versus-Host Disease in Determining Long-Term Survival after Allogeneic Transplantation. Biol Blood Marrow Transplant. 2019 08; 25(8):1682-1688.
    View in: PubMed
    Score: 0.009
  12. Cognitive Function and Quality of Life in Vorinostat-Treated Patients after Matched Unrelated Donor Myeloablative Conditioning Hematopoietic Cell Transplantation. Biol Blood Marrow Transplant. 2019 02; 25(2):343-353.
    View in: PubMed
    Score: 0.008
  13. MAGIC biomarkers predict long-term outcomes for steroid-resistant acute GVHD. Blood. 2018 06 21; 131(25):2846-2855.
    View in: PubMed
    Score: 0.008
  14. An early-biomarker algorithm predicts lethal graft-versus-host disease and survival. JCI Insight. 2017 02 09; 2(3):e89798.
    View in: PubMed
    Score: 0.008
  15. Infectious Risk after Allogeneic Hematopoietic Cell Transplantation Complicated by Acute Graft-versus-Host Disease. Biol Blood Marrow Transplant. 2017 Mar; 23(3):522-528.
    View in: PubMed
    Score: 0.008
  16. Combination Therapy for Graft-versus-Host Disease Prophylaxis with Etanercept and Extracorporeal Photopheresis: Results of a Phase II Clinical Trial. Biol Blood Marrow Transplant. 2016 May; 22(5):862-8.
    View in: PubMed
    Score: 0.007
  17. FLT3 mutational status is an independent risk factor for adverse outcomes after allogeneic transplantation in AML. Bone Marrow Transplant. 2016 Apr; 51(4):511-520.
    View in: PubMed
    Score: 0.007
  18. Allogeneic transplantation with myeloablative FluBu4 conditioning improves survival compared to reduced intensity FluBu2 conditioning for acute myeloid leukemia in remission. Ann Hematol. 2015 Jun; 94(6):1033-41.
    View in: PubMed
    Score: 0.007
  19. TNF-inhibition with etanercept for graft-versus-host disease prevention in high-risk HCT: lower TNFR1 levels correlate with better outcomes. Biol Blood Marrow Transplant. 2012 Oct; 18(10):1525-32.
    View in: PubMed
    Score: 0.005
  20. Plasma biomarkers of lower gastrointestinal and liver acute GVHD. Blood. 2012 Mar 22; 119(12):2960-3.
    View in: PubMed
    Score: 0.005
  21. Regenerating islet-derived 3-alpha is a biomarker of gastrointestinal graft-versus-host disease. Blood. 2011 Dec 15; 118(25):6702-8.
    View in: PubMed
    Score: 0.005
  22. Clofarabine and busulfan conditioning facilitates engraftment and provides significant antitumor activity in nonremission hematologic malignancies. Blood. 2011 Oct 13; 118(15):4258-64.
    View in: PubMed
    Score: 0.005
  23. Frequency of CD4(+)CD25(hi)FOXP3(+) regulatory T cells has diagnostic and prognostic value as a biomarker for acute graft-versus-host-disease. Biol Blood Marrow Transplant. 2010 Jul; 16(7):907-14.
    View in: PubMed
    Score: 0.005
  24. Elafin is a biomarker of graft-versus-host disease of the skin. Sci Transl Med. 2010 Jan 06; 2(13):13ra2.
    View in: PubMed
    Score: 0.005
  25. A biomarker panel for acute graft-versus-host disease. Blood. 2009 Jan 08; 113(2):273-8.
    View in: PubMed
    Score: 0.004
  26. Etanercept plus methylprednisolone as initial therapy for acute graft-versus-host disease. Blood. 2008 Feb 15; 111(4):2470-5.
    View in: PubMed
    Score: 0.004
  27. Pilot trial on the use of etanercept and methylprednisolone as primary treatment for acute graft-versus-host disease. Biol Blood Marrow Transplant. 2005 Sep; 11(9):680-7.
    View in: PubMed
    Score: 0.003
  28. Treatment of chronic graft-versus-host disease with anti-CD20 chimeric monoclonal antibody. Biol Blood Marrow Transplant. 2003 Aug; 9(8):505-11.
    View in: PubMed
    Score: 0.003
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.